抗TNF与硫嘌呤预防克罗恩病术后复发的风险预测与疗效比较:6项试验的汇总分析
该个体参与者数据荟萃分析纳入6项随机对照试验共645例回结肠切除术后克罗恩病患者,比较抗TNF-α与硫嘌呤预防术后复发的效果。结果显示抗TNF-α在降低内镜复发、临床复发和严重内镜复发方面均优于硫嘌呤,且优势在低危和高危亚组中均存在。
要点
- 抗TNF-α预防术后内镜复发的效果优于硫嘌呤(RR 0.52)。
- 抗TNF-α同样降低临床复发和严重内镜复发风险。
- 既往抗TNF暴露和穿透性疾病行为与内镜复发风险相关。
核心结论
- 抗TNF-α预防回结肠切除术后克罗恩病内镜和临床复发优于硫嘌呤。
- 抗TNF-α的优势在亚组分析和风险分层后得到确认。
研究设计与样本
- 系统检索后获取研究硫嘌呤和/或抗TNF-α的随机对照试验的个体参与者数据。
- 共纳入6项研究645例参与者,采用固定效应网络荟萃分析。
- 使用泊松回归建立预测模型,纳入性别、吸烟、蒙特利尔分型、CD病程、既往切除史和既往抗TNF-α或硫嘌呤暴露。
主要发现
- 抗TNF-α相比硫嘌呤预防内镜复发的RR为0.52(95%CI 0.33-0.80)。
- 抗TNF-α相比硫嘌呤预防临床复发的RR为0.50(95%CI 0.26-0.96)。
- 抗TNF-α相比硫嘌呤预防严重内镜复发的RR为0.41(95%CI 0.21-0.79)。
- 内镜复发未发现亚组效应差异。
- 泊松回归中既往抗TNF-α暴露和穿透性疾病行为与内镜复发风险相关。
关键数值与推荐
- 主要结局为内镜复发(Rutgeerts评分≥i2)。
- 次要结局为临床复发(Harvey-Bradshaw指数/克罗恩病活动指数评分)和严重内镜复发(Rutgeerts评分≥i3)。
临床怎么用
- 对于回结肠切除术后克罗恩病患者,可优先考虑抗TNF-α而非硫嘌呤预防复发。
- 风险评估可参考既往抗TNF-α暴露和穿透性疾病行为。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The superiority of anti-TNF-α agents to thiopurines for the prevention of postoperative recurrence of Crohn's disease (CD) after ileocolonic resection remains controversial. In this meta-analysis of individual participant data (IPD), the effect of both strategies was compared and assessed after risk stratification. METHODS: After a systematic literature search, IPD were requested from randomized controlled trials investigating thiopurines and/or anti-TNF-α agents after ileocolonic resection. Primary outcome was endoscopic recurrence (ER) (Rutgeerts score ≥i2) and secondary outcomes were clinical recurrence (Harvey-Bradshaw Index/Crohn's Disease Activity Index score) and severe ER (Rutgeerts score ≥i3). A fixed effect network meta-analysis was performed. Subgroup effects were assessed and a prediction model was established using Poisson regression models, including sex, smoking, Montreal classification, CD duration, history of prior resection and previous exposure to anti-TNF-α or thiopurines. RESULTS: In the meta-analysis of IPD, 645 participants from 6 studies were included. In the total population, a superior effect was demonstrated for anti-TNF-α compared with thiopurine prophylaxis for ER (relative risk [RR], 0.52; 95% confidence interval [CI], 0.33-0.80), clinical recurrence (RR, 0.50; 95% CI, 0.26-0.96), and severe ER (RR, 0.41; 95% CI, 0.21-0.79). No differential subgroup effects were found for ER. In Poisson regression analysis, previous exposure to anti-TNF-α and penetrating disease behavior were associated with ER risk. The advantage of anti-TNF-α agents as compared with thiopurines was observed in low- and high-risk groups. CONCLUSIONS: Anti-TNF-α is superior to thiopurine prophylaxis for the prevention of endoscopic and clinical postoperative CD recurrence after ileocolonic resection. The advantage of anti-TNF-α agents was confirmed in subgroup analysis and after risk stratification.
引用
- Beelen EMJ, Nieboer D, Arkenbosch JHC, et al. Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. Clin Gastroenterol Hepatol. 2021. PMID: 34687970. doi:10.1016/j.cgh.2021.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。